Highlights in GI Oncology 2024

Orlando, FL US
February 23, 2024 to February 24, 2024

 

 

Highlights in GI Oncology is a program designed to provide the latest science and education from the world’s premier GI oncology event, the ASCO Gastrointestinal Cancers Symposium. The abstracts selected for presentation and discussion reflect the foremost research and strategies in oncology that will impact clinical practice and patient care.

The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in GI cancer treatment. Expert faculty will review the findings, discuss the results potential impact on the current standard of care, and apply the results within the clinical context of a patient case.

Learning Objectives

  1. Summarize key advances presented at the ASCO GI Cancers Symposium
  2. Review the latest data for the perioperative and advanced treatment of GI cancers
  3. Apply the latest clinical data to practice to optimize care and outcomes for patients with GI cancers
  4. Identify the latest advances for the role of molecular testing in the management of gastrointestinal malignancies
  5. Discuss current challenges and controversies in the management of GI cancers

 

 Designation

Early Bird 
Deadline November 23, 2023

Advanced
Deadline January 23, 2024

General Registration
Deadline February 23, 2024

 Physicians$125$175$225

 Pharmacists

$75

$100$125

 NPs, PAs, RNs, and others

$60

$85$110

 Pharma / Med Device Company Employee**

$325

$375$425

 Students & Fellows*

$Free*

Refunds of 50% of the registration fee will be provided if you cancel up to 30 days before Highlights in GI Oncology 2024 commences.  There are no refunds for cancellations within the 30-day window of the start of the event.  To request a refund, please email info@horizoncme.com

**Defined as anyone employed by a drug, device, or diagnostic company. We allow Industry Professionals to register for our conferences unless you are employed in a sales role with your company. Please note that we will accept a limited number of Industry Professionals (excluding sales) to each conference.

*Student is defined as currently enrolled in an advanced learning institution and/or studying in order to enter a particular profession. If you would like to attend as a Student, please contact info@horizoncme.com for further information.

 

Horizon CME will NOT provide international travelers with an invitation letter to attend this in-person activity. If you reside outside the United States or Canada and register and pay for this event, AND you are unable to obtain a visa to attend, no refund will be issued.

Intended Learners

This CME initiative is designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with GI cancers. Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email/mailing address and payment information). This information is confidential and will only be used to contact you regarding your registration. Cancellation Policy: Fees are non-refundable and non-transferable.

Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.

 

Presented By

                      

Course summary
Available credit: 
  • 8.25 ACPE Pharmacy
    The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 8.25 credit by the Washington State Pharmacy Association.

    This activity is approved for up to 8.25 credit by the Washington State Pharmacy Association. ACPE#: 0130-9999-21--L01-P | Activity Type: Live| Start/End date: Fri, 02/23/2024 - 11:00am-Sat, 02/24/2024 - 1:45pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 50 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171
  • 8.25 AMA PRA Category 1 Credit
    Horizon CME designates this Live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 8.25 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 8.25 credit.
  • 3.50 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 3.50 credit.
Course opens: 
07/18/2023
Course expires: 
03/24/2024
Event starts: 
02/23/2024 - 11:00am PST
Event ends: 
02/24/2024 - 1:45pm PST
Cost:
$110.00
Rating: 
0

Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.

All Times Listed are for the Eastern Standard Time Zone

Friday, February 23, 2024

2:00pm Registration Open and Set Up
2:30pm Welcome, Introductions, & CE/CME Housekeeping
2:40pm (01) Neuroendocrine Cancers
» Aman Chauhan, MD - Sylvester Comprehensive Cancer Center
3:25pmGather Lunch
3:30pmBuffet Lunch & Non-CE/CME Symposium Presentation Sponsored by: Taiho Oncology - LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer
» Michael Morse, MD
4:20pm(02) Colon Cancer
» Cathy Eng, MD - Vanderbilt University Medical Center
4:50pm Break - Trivia for Charity in the Exhibit Hall
5:00pm (03) Rectal Cancer (Case Based Discussion)
» Moderator: Jeremy C. Jones, MD - Division of Hematology and Medical Oncology Mayo Clinic
» Kristen Ciombor, MD, MSCI - Vanderbilt University Medical Center
» Christopher Aquina, MD, MPH - General Surgery Specialist Advent Health Cancer Institute
» Sarah Hoffe, MD - Interim Chair GI Radiation Oncology Moffitt Cancer Center
6:00pm Network Reception in Exhibit Hall

Saturday, February 24, 2024

7:00am Check-in & Breakfast Available in Exhibit Hall
7:50am Welcome, Introductions, & CE/CME Housekeeping
8:00am (04) Hepatobiliary Cancers: Are We Looking at the Big Picture?
» Ghassan K. Abou-Alfa, MD, MBA - Memorial Sloan Kettering Cancer Center
9:00am (05) Molecular Testing in GI Oncology
» Aaron J. Scott, MD - University of Arizona Cancer Center - Tucson
9:45am (06) Stump the Faculty
10:00am Break - Refreshments in Exhibit Hall
10:30am (07) Pancreatic Cancer: Metastatic
» Eileen M. O'Reilly, MD - Memorial Sloan Kettering Cancer Center
11:30am (08) Pancreatic Cancer: Perioperative
» Philip A. Philip, MD, PhD, FRCP - Wayne State University
12:00pm (09) Stump the Faculty
12:15pm Gather for Lunch
12:20pmBuffet Lunch & Non-CE/CME Symposium Presentation Sponsored by: Bristol Myers Squibb - Opdivo plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal cancers
» Ingrid Rivera, Bristol Myers Squibb
1:10pm Dessert Break in Exhibit Hall
1:35pm (10) Hepatocellular Carcinoma
» Stacy Stein, MD - Yale School of Medicine
2:05pm (11) Biliary Cancer
» Milind Javie, MD - The University of Texas MD Anderson Cancer Center
2:35pm (12) Stump the Faculty
2:50pm Break - Refreshments in Exhibit Hall
3:20pm (13) Non-Metastatic Esophageal and Gastric Cancer GE Junction Patient Cases - Locally Advanced vs Metastatic
» Moderator: Rutika Mehta, MD, MPH - Moffitt Cancer Center
» Ravi Shridhar, MD, PhD - AdventHealth
» Jose M. Pimiento, MD - Moffitt Cancer Center
4:20pm (14) Metastatic Esophageal and Gastric Cancer
» Jason Starr, DO - Mayo Clinic
4:50pm Closing Comments
Rosen Shingle Creek
9939 Universal Blvd
Orlando, FL 32819
United States
+1 (407) 996-9939

We want to ensure that your time at the Highlights in GI Oncology 2024 conference is convenient and memorable. Staying at our host hotel provides a hassle-free experience and puts you at the heart of the activity surrounding the conference.

Booking Deadline: SOLD OUT

 

Planning Committee Members

Hani Babiker, MD

Pancreaticobiliary, GI Oncology

Early Phase Therapeutics, and Senior Associate Consultant

Mayo Clinic Jacksonville, FL

 

Dr. Hani Babiker is an Oncologist with board certification in Oncology and Hematology and initial certification in Internal Medicine and Geriatrics and Gerontology. He held academic appointments at the Translational Genomics Research Institute (TGen) and the University of Arizona. Prior to joining the Mayo Clinic, he was the Director of the Early Phase Clinical Trials Program and Co-Chair of DSMB at the University of Arizona Cancer Center. His research interests are in new drug development and in the treatment of gastrointestinal cancers with an emphasis on pancreatic cancer. He completed a drug development scholarship at the Virginia G Piper Cancer Center Clinical Trials/HonorHealth Research Institute in Scottsdale where he served as the principal investigator in many early phase clinical trials in solid tumors and participated in trials that led to drug approvals. He also has an interest both in developing new biomarkers and targeted therapies in pancreatic cancer. Dr. Babiker is currently the Associate Director, Clinical Research Operations Mayo Clinic Cancer Center, FL.

Dr. Babiker earned his M.D. with High Honors from Univerzita Komenskeho, Slovakia, and completed a residency in Internal Medicine and a fellowship in Geriatrics and Gerontology at Weill Cornell Medical College, New York Presbyterian Hospital. Dr. Babiker was an instructor in medicine at the Mayo Clinic College of Medicine in Phoenix. He also completed a Hematology and Medical Oncology fellowship at the University of Arizona where he also served as Chief Fellow. Dr. Babiker is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the American College of Physicians. He has authored several abstracts and peer review manuscripts and has a passion for teaching and mentoring students and trainees.

 

Jeremy C. Jones, MD

Assistant Professor of Oncology Vice Chair

Clinical Practice Division of Hematology and Medical Oncology

Mayo Clinic Jacksonville, FL

 

Jeremy C. Jones, is a medical oncologist and hematologist who specializes in treating gastrointestinal malignancies.

His clinical focus includes:
• Colorectal cancer
• Esophageal cancer
• Anal cancer

His research interests include cancer therapeutic trials as well as studying the underlying molecular genetics that drive gastrointestinal malignancies.

 

Rutika Mehta, MD, MPH

Medical Oncologist

Moffitt Cancer Center Tampa, FL

 

Dr. Rutika Mehta is an Associate Member in the Department of GI Oncology at Moffitt Cancer Center and Assistant Professor in the Department of Oncological Sciences at University of South Florida. She is extremely passionate in helping patients with GI cancers especially esophageal and gastric cancers with new and cutting edge clinical trials. Her research interests are in cancer genomics and cancers in ethnic minorities and the intersection of genomics and ethnicity. She also serves on the medical advisory board for Debbie’s Dream Foundation which is a non-profit organization that supports patients with gastric cancer.

 

Mohamedtaki Tejani, MD 

Medical Director

GI Oncology Program

Advent Health Cancer Institute Orlando, FL

 

Mohamedtaki A. Tejani received his Bachelor of Arts degree, magna cum laude from Amherst College. He later earned his medical degree from Dartmouth Medical School. Dr. Tejani went on to complete his residency at Yale-New Haven Hospital in New Haven, CT, achieving the rank of Chief Resident. Following this, he completed his fellowship training in hematology/oncology at Fox Chase Cancer Center/Temple University in Philadelphia.

An award-winning physician, Dr. Tejani has authored numerous oncology-related publications. His research experience and areas of interest include gastrointestinal cancers, biomarkers and therapeutics, patient-provider communication and the culture of medicine.  Dr. Tejani firmly believes that patient care is a privilege. Listening and responding to a patient's unique story is critical in helping that family on their cancer journey. Originally from Tanzania (East Africa), he is fluent in Swahili, Hindi, Urdu and Gujarati.

Available Credit

  • 8.25 ACPE Pharmacy
    The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 8.25 credit by the Washington State Pharmacy Association.

    This activity is approved for up to 8.25 credit by the Washington State Pharmacy Association. ACPE#: 0130-9999-21--L01-P | Activity Type: Live| Start/End date: Fri, 02/23/2024 - 11:00am-Sat, 02/24/2024 - 1:45pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 50 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171
  • 8.25 AMA PRA Category 1 Credit
    Horizon CME designates this Live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 8.25 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 8.25 credit.
  • 3.50 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 3.50 credit.

Price

Cost:
$110.00
Please login or register to take this course.